טוען...
Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
Inflammatory myofibroblastic tumor (IMT), a rare sarcoma, is primarily treated via resection of the mass. However, in cases of recurrence or unresectable tumors, no standard care exists. While crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, is only approved for non-small-cell lung cancer...
שמור ב:
| הוצא לאור ב: | Intern Med |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The Japanese Society of Internal Medicine
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6478978/ https://ncbi.nlm.nih.gov/pubmed/30449794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.1640-18 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|